Generation of functional canine TIL products for solid tumors
-
By
-
Kay M. Foos
-
Veethika Pandey
-
Michael W. Jennings
-
Daniel J. Powell
-
Nicola J. Mason
-
May 13, 2026
-
Clinical Scorecard: Development of Viable Canine Tumor-Infiltrating Lymphocyte Products for Solid Tumor Treatment
At a Glance
| Category | Detail |
|---|
| Condition | Canine tumors, specifically oral melanoma and appendicular osteosarcoma |
| Key Mechanisms | Adoptive cell transfer of tumor-infiltrating lymphocytes (TILs) |
| Target Population | Client-owned dogs with naturally occurring tumors |
| Care Setting | Veterinary oncology |
Key Highlights
- TIL therapy shows promise in canine oral melanoma and appendicular osteosarcoma.
- Canine tumors have a low tumor mutational burden (TMB), presenting unique challenges for TIL therapy.
- Canine models provide a more accurate representation of tumor-immune interactions compared to murine models.
- TILs can be expanded from canine tumors despite low T cell frequencies.
- The study establishes a foundation for future comparative trials on TIL efficacy.
Guideline-Based Recommendations
Diagnosis
- Characterize canine TIL reactivity against autologous tumor cells.
Management
- Develop protocols for the expansion of TILs from canine tumors.
Monitoring & Follow-up
- Assess immune responses and tumor progression in treated dogs.
Risks
- Potential for an immunosuppressive tumor microenvironment affecting TIL efficacy.
Patient & Prescribing Data
Dogs with oral melanoma and appendicular osteosarcoma
TIL therapy may enhance treatment options for dogs with low TMB malignancies.
Clinical Best Practices
- Utilize client-owned dogs for translational research in immunotherapy.
- Focus on developing TIL products that are reactive to autologous tumor cells.
- Consider the unique tumor microenvironment when designing TIL therapies.
Related Resources & Content
